Modern options in personalized therapy of metastatic cutaneous melanoma

Modern options in personalized therapy of metastatic cutaneous melanoma

A great progress was recently achieved in metastatic melanoma therapy. New targeted therapies allow high efficacy expectations for personalized treatment approaches. BRAF-inhibitors significantly increase time to progression, overall survival and response rate in malignant melanoma patients. Vemuraf...

Full description

Bibliographic Details
Main Authors:	S A Protsenko, A V Novik, Z Yu Akhaeva, A S Zhabina, E N Imyanitov, A I Semenova
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2014-09-01
Series:	Современная онкология
Subjects:	metastatic melanoma targeted therapy braf-inhibitors vemurafenib
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/26968

Similar Items

Modern combined targeted and immunotherapy of metastatic skin melanoma
by: S. A. Protsenko, et al.
Published: (2020-12-01)

Analysis of survival at metastatic melanoma patients treated with vemurafenib: A three year single institution study
by: Gojković Zdenka, et al.
Published: (2018-01-01)

Metastatic melanoma and vemurafenib: novel approaches
by: Ramon Andrade De Mello
Published: (2012-04-01)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
by: Elzbieta Nowara, et al.
Published: (2016-02-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

The role of BRAF V600 mutation in melanoma
by: Ascierto Paolo A, et al.
Published: (2012-07-01)

Therapy for metastatic melanoma: the past, present, and future
by: Finn Laura, et al.
Published: (2012-03-01)

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
by: Hilal Eser Öztürk, et al.
Published: (2020-01-01)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
by: Castellani Elisa, et al.
Published: (2012-07-01)

Cutaneous side-effects during therapy of melanoma by vemurafenib
by: Anna Ankudowicz, et al.
Published: (2015-06-01)

By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma
by: Mmohammad Erfan Zare, et al.
Published: (2012-01-01)

By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma
by: Mehrdad Payandeh, et al.
Published: (2012-03-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin
by: Yu-Ching Weng, et al.
Published: (2016-06-01)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01)

Targeted therapy; from advanced melanoma to the adjuvant setting
by: Antonio eAhn, et al.
Published: (2013-08-01)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
by: Morgane Broudic-Guibert, et al.
Published: (2019-07-01)

Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
by: Stephen A. Luebker, et al.
Published: (2019-04-01)

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
by: Meghan J. Mooradian, et al.
Published: (2018-05-01)

BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
by: Chowdhary M, et al.
Published: (2016-12-01)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
by: Joseph I. Clark, et al.
Published: (2018-07-01)

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
by: Kristina V. Orlova, et al.
Published: (2021-05-01)

Modulação dos efeitos citotóxicos dos vemurafenibe pela cloroquina em células de melanoma maligno G-361: papel da dermicidina.
by: Jennifer Eliana Montoya Neyra
Published: (2017)

Modulação dos efeitos citotóxicos dos vemurafenibe pela cloroquina em células de melanoma maligno G-361: papel da dermicidina.
by: Neyra, Jennifer Eliana Montoya
Published: (2017)

Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib
by: Carine Houriet, et al.
Published: (2014-09-01)

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
by: Jorine de Haan, et al.
Published: (2018-02-01)

RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
by: Kun Zhao, et al.
Published: (2020-06-01)

Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review
by: Aurélien Simon, et al.
Published: (2017-01-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
by: Bartoušková Marie, et al.
Published: (2020-08-01)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
by: Tran KA, et al.
Published: (2015-12-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Ebner, R., et al.
Published: (2022)

Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients
by: Sarah Zhou, et al.
Published: (2021-05-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
by: Polsky David, et al.
Published: (2004-12-01)

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
by: Baptiste Louveau, et al.
Published: (2019-08-01)

Targeting the ERK Signaling Pathway in Melanoma
by: Paola Savoia, et al.
Published: (2019-03-01)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
by: Yufan Tan, et al.
Published: (2021-06-01)

Cannot write session to /tmp/vufind_sessions/sess_mpctlpj4embtskbkc8jqq76beg